Severe asthma often requires biologic therapies such as dupilumab and tezepelumab, yet their long-term comparative efficacy remains uncertain due to limited head-to-head evidence. To address this gap, a study used an unanchored matching-adjusted indirect comparison to evaluate the long-term relative efficacy of dupilumab versus tezepelumab in 1,368 patients with severe asthma . The study found that dupilumab significantly reduced the annualized exacerbation rate compared with tezepelumab (mean difference (MD) −0.269), while rates of severe exacerbations requiring hospitalization or ER visits were similar (MD: 0.006).
Dupilumab also showed greater improvement in lung function, with a significant increase in forced expiratory volume (FEV1) in severe asthma (MD: −0.153) and a numerical improvement overall (MD: −0.064). These findings suggest that long-term dupilumab treatment reduces…
